Defence Therapeutics: Developing Next Generation Biopharmaceutical Innovations

October 26, 2022

Stocks to Invest in: Healthcare

Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cell.

Defence Therapeutics is a Canadian Biotech developing next generation biopharmaceutical innovations for various immuno-oncology (IO) and infectiousdiseases (ID) indications

For more information on Defence Therapeutics Inc. (CSE: DTC, OTC: DTCFF) please click the request investor info button.


You might also like

Healthcare
Defence Therapeutics: Revolutionizing Immune-Related Therapies with ACCUM Technology

Defence Therapeutics is a Canadian biotech company developing immune-related therapies using their proprietary ACCUM technology.

Healthcare
Investor Alert - Defence Therapeutics: Developing Immune-related Therapies for Cancer Treatment

Defence Therapeutics is a Canadian biotech company developing immune-related therapies for cancer treatment, including cancer vaccines, antibodies, and drug delivery vehicles.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, YouTube and more!